Aldose reductase inhibitors: the end of an era or the need for different trial designs?
Related Experiment Videos
M A Pfeifer1, M P Schumer, D A Gelber
1Department of Internal Medicine, East Carolina University School of Medicine, Greenville, North Carolina 27858, USA.
Abstract:
Despite numerous attempts over 16 years, the results of aldose reductase inhibitor (ARI) trials for the treatment of diabetic neuropathy have not proven efficacy. This paper reviews each of the ARI trials, examines confounding factors, and proposes a future course. The confounding factors considered are pharmacokinetics (ARI penetration of human nerve), length of trial (in terms of the natural history of diabetic neuropathy), trial endpoints (reversibility or slowing of progression), reproducibility of clinical measurements (in terms of power calculations), standardization and quality control of endpoints, and clinically meaningful differences in endpoints. We conclude that ARIs are most likely to have a beneficial effect in the management of diabetic distal symmetrical polyneuropathy and autonomic neuropathy but that the clinical role of ARIs is to slow the progression of diabetic neuropathy rather than to reverse it. Future trials should be designed with adequate statistical power, with consideration of the variability of the endpoint measurements for long enough duration, and with rigorous quality control to definitively confirm the utility of ARIs in the treatment of diabetic distal symmetrical polyneuropathy and autonomic neuropathy.
Insights
Aldose reductase inhibitors (ARIs) show potential for slowing diabetic neuropathy progression, not reversing it. Future trials need better design for definitive efficacy confirmation in diabetic distal symmetrical polyneuropathy and autonomic neuropathy.
Area of Science:
- Neuroscience
- Pharmacology
- Diabetology
Background:
- Diabetic neuropathy remains a significant complication of diabetes.
- Aldose reductase inhibitors (ARIs) have been investigated for 16 years to treat diabetic neuropathy.
- Previous clinical trials have largely failed to demonstrate ARI efficacy.
Purpose of the Study:
- To review aldose reductase inhibitor (ARI) trials for diabetic neuropathy.
- To examine confounding factors that may have affected trial outcomes.
- To propose a future research direction for ARI development.
Main Methods:
- Review of published aldose reductase inhibitor (ARI) clinical trial data.
- Analysis of pharmacokinetic properties, including drug penetration into human nerve tissue.
- Evaluation of trial design elements: duration, endpoints, measurement reproducibility, and quality control.
Main Results:
- Confounding factors identified include pharmacokinetics, trial length, endpoint selection (reversibility vs. slowing progression), measurement variability, and standardization.
- Aldose reductase inhibitors (ARIs) are most promising for diabetic distal symmetrical polyneuropathy and autonomic neuropathy.
- The primary clinical role of ARIs appears to be slowing disease progression rather than achieving reversal.
Conclusions:
- Future aldose reductase inhibitor (ARI) trials require adequate statistical power and duration.
- Rigorous quality control and consideration of endpoint variability are crucial for definitive results.
- ARIs may offer a beneficial role in managing diabetic distal symmetrical polyneuropathy and autonomic neuropathy by slowing progression.